Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor

R. Bertini, L. S. Barcelos, A. R. Beccari, B. Cavalieri, A. Moriconi, C. Bizzarri, P. Di Benedetto, C. Di Giacinto, I. Gloaguen, E. Galliera, M. M. Corsi, R. C. Russo, S. P. Andrade, M. C. Cesta, G. Nano, A. Aramini, J. C. Cutrin, M. Locati, M. Allegretti, M. M. Teixeira

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Background and Purpose DF 2156A is a new dual inhibitor of IL-8 receptors CXCR1 and CXCR2 with an optimal pharmacokinetic profile. We characterized its binding mode, molecular mechanism of action and selectivity, and evaluated its therapeutic potential. Experimental Approach The binding mode, molecular mechanism of action and selectivity were investigated using chemotaxis of L1.2 transfectants and human leucocytes, in addition to radioligand and [ 35S]-GTPγS binding approaches. The therapeutic potential of DF 2156A was evaluated in acute (liver ischaemia and reperfusion) and chronic (sponge-induced angiogenesis) experimental models of inflammation. Key Results A network of polar interactions stabilized by a direct ionic bond between DF 2156A and Lys99 on CXCR1 and the non-conserved residue Asp 293 on CXCR2 are the key determinants of DF 2156A binding. DF 2156A acted as a non-competitive allosteric inhibitor blocking the signal transduction leading to chemotaxis without altering the binding affinity of natural ligands. DF 2156A effectively and selectively inhibited CXCR1/CXCR2-mediated chemotaxis of L1.2 transfectants and leucocytes. In a murine model of sponge-induced angiogenesis, DF 2156A reduced leucocyte influx, TNF-α production and neovessel formation. In vitro, DF 2156A prevented proliferation, migration and capillary-like organization of HUVECs in response to human IL-8. In a rat model of liver ischaemia and reperfusion (I/R) injury, DF 2156A decreased PMN and monocyte-macrophage infiltration and associated hepatocellular injury. Conclusion and Implications DF 2156A is a non-competitive allosteric inhibitor of both IL-8 receptors CXCR1 and CXCR2. It prevented experimental angiogenesis and hepatic I/R injury in vivo and, therefore, has therapeutic potential for acute and chronic inflammatory diseases.

Original languageEnglish
Pages (from-to)436-454
Number of pages19
JournalBritish Journal of Pharmacology
Volume165
Issue number2
DOIs
Publication statusPublished - Jan 2012

Fingerprint

Pharmacology
Chemotaxis
Interleukin-8 Receptors
Leukocytes
Porifera
Reperfusion Injury
Liver
2'-((4'-trifluoromethanesulfonyloxy)phenyl)-N-methanesulfonylpropionamide
Interleukin-8
Reperfusion
Monocytes
Signal Transduction
Chronic Disease
Theoretical Models
Therapeutics
Ischemia
Pharmacokinetics
Macrophages
Ligands
Inflammation

Keywords

  • binding mode
  • chemokine receptors
  • CXCR1/CXCR2
  • experimental angiogenesis
  • ischaemia reperfusion injury
  • leucocyte recruitment
  • non-competitive allosteric inhibitor

ASJC Scopus subject areas

  • Pharmacology

Cite this

Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor. / Bertini, R.; Barcelos, L. S.; Beccari, A. R.; Cavalieri, B.; Moriconi, A.; Bizzarri, C.; Di Benedetto, P.; Di Giacinto, C.; Gloaguen, I.; Galliera, E.; Corsi, M. M.; Russo, R. C.; Andrade, S. P.; Cesta, M. C.; Nano, G.; Aramini, A.; Cutrin, J. C.; Locati, M.; Allegretti, M.; Teixeira, M. M.

In: British Journal of Pharmacology, Vol. 165, No. 2, 01.2012, p. 436-454.

Research output: Contribution to journalArticle

Bertini, R, Barcelos, LS, Beccari, AR, Cavalieri, B, Moriconi, A, Bizzarri, C, Di Benedetto, P, Di Giacinto, C, Gloaguen, I, Galliera, E, Corsi, MM, Russo, RC, Andrade, SP, Cesta, MC, Nano, G, Aramini, A, Cutrin, JC, Locati, M, Allegretti, M & Teixeira, MM 2012, 'Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor', British Journal of Pharmacology, vol. 165, no. 2, pp. 436-454. https://doi.org/10.1111/j.1476-5381.2011.01566.x
Bertini, R. ; Barcelos, L. S. ; Beccari, A. R. ; Cavalieri, B. ; Moriconi, A. ; Bizzarri, C. ; Di Benedetto, P. ; Di Giacinto, C. ; Gloaguen, I. ; Galliera, E. ; Corsi, M. M. ; Russo, R. C. ; Andrade, S. P. ; Cesta, M. C. ; Nano, G. ; Aramini, A. ; Cutrin, J. C. ; Locati, M. ; Allegretti, M. ; Teixeira, M. M. / Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor. In: British Journal of Pharmacology. 2012 ; Vol. 165, No. 2. pp. 436-454.
@article{6e6ab0f2de6b4c48a0345b6e48bfbb80,
title = "Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor",
abstract = "Background and Purpose DF 2156A is a new dual inhibitor of IL-8 receptors CXCR1 and CXCR2 with an optimal pharmacokinetic profile. We characterized its binding mode, molecular mechanism of action and selectivity, and evaluated its therapeutic potential. Experimental Approach The binding mode, molecular mechanism of action and selectivity were investigated using chemotaxis of L1.2 transfectants and human leucocytes, in addition to radioligand and [ 35S]-GTPγS binding approaches. The therapeutic potential of DF 2156A was evaluated in acute (liver ischaemia and reperfusion) and chronic (sponge-induced angiogenesis) experimental models of inflammation. Key Results A network of polar interactions stabilized by a direct ionic bond between DF 2156A and Lys99 on CXCR1 and the non-conserved residue Asp 293 on CXCR2 are the key determinants of DF 2156A binding. DF 2156A acted as a non-competitive allosteric inhibitor blocking the signal transduction leading to chemotaxis without altering the binding affinity of natural ligands. DF 2156A effectively and selectively inhibited CXCR1/CXCR2-mediated chemotaxis of L1.2 transfectants and leucocytes. In a murine model of sponge-induced angiogenesis, DF 2156A reduced leucocyte influx, TNF-α production and neovessel formation. In vitro, DF 2156A prevented proliferation, migration and capillary-like organization of HUVECs in response to human IL-8. In a rat model of liver ischaemia and reperfusion (I/R) injury, DF 2156A decreased PMN and monocyte-macrophage infiltration and associated hepatocellular injury. Conclusion and Implications DF 2156A is a non-competitive allosteric inhibitor of both IL-8 receptors CXCR1 and CXCR2. It prevented experimental angiogenesis and hepatic I/R injury in vivo and, therefore, has therapeutic potential for acute and chronic inflammatory diseases.",
keywords = "binding mode, chemokine receptors, CXCR1/CXCR2, experimental angiogenesis, ischaemia reperfusion injury, leucocyte recruitment, non-competitive allosteric inhibitor",
author = "R. Bertini and Barcelos, {L. S.} and Beccari, {A. R.} and B. Cavalieri and A. Moriconi and C. Bizzarri and {Di Benedetto}, P. and {Di Giacinto}, C. and I. Gloaguen and E. Galliera and Corsi, {M. M.} and Russo, {R. C.} and Andrade, {S. P.} and Cesta, {M. C.} and G. Nano and A. Aramini and Cutrin, {J. C.} and M. Locati and M. Allegretti and Teixeira, {M. M.}",
year = "2012",
month = "1",
doi = "10.1111/j.1476-5381.2011.01566.x",
language = "English",
volume = "165",
pages = "436--454",
journal = "British Journal of Pharmacology",
issn = "0007-1188",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2 non-competitive allosteric inhibitor

AU - Bertini, R.

AU - Barcelos, L. S.

AU - Beccari, A. R.

AU - Cavalieri, B.

AU - Moriconi, A.

AU - Bizzarri, C.

AU - Di Benedetto, P.

AU - Di Giacinto, C.

AU - Gloaguen, I.

AU - Galliera, E.

AU - Corsi, M. M.

AU - Russo, R. C.

AU - Andrade, S. P.

AU - Cesta, M. C.

AU - Nano, G.

AU - Aramini, A.

AU - Cutrin, J. C.

AU - Locati, M.

AU - Allegretti, M.

AU - Teixeira, M. M.

PY - 2012/1

Y1 - 2012/1

N2 - Background and Purpose DF 2156A is a new dual inhibitor of IL-8 receptors CXCR1 and CXCR2 with an optimal pharmacokinetic profile. We characterized its binding mode, molecular mechanism of action and selectivity, and evaluated its therapeutic potential. Experimental Approach The binding mode, molecular mechanism of action and selectivity were investigated using chemotaxis of L1.2 transfectants and human leucocytes, in addition to radioligand and [ 35S]-GTPγS binding approaches. The therapeutic potential of DF 2156A was evaluated in acute (liver ischaemia and reperfusion) and chronic (sponge-induced angiogenesis) experimental models of inflammation. Key Results A network of polar interactions stabilized by a direct ionic bond between DF 2156A and Lys99 on CXCR1 and the non-conserved residue Asp 293 on CXCR2 are the key determinants of DF 2156A binding. DF 2156A acted as a non-competitive allosteric inhibitor blocking the signal transduction leading to chemotaxis without altering the binding affinity of natural ligands. DF 2156A effectively and selectively inhibited CXCR1/CXCR2-mediated chemotaxis of L1.2 transfectants and leucocytes. In a murine model of sponge-induced angiogenesis, DF 2156A reduced leucocyte influx, TNF-α production and neovessel formation. In vitro, DF 2156A prevented proliferation, migration and capillary-like organization of HUVECs in response to human IL-8. In a rat model of liver ischaemia and reperfusion (I/R) injury, DF 2156A decreased PMN and monocyte-macrophage infiltration and associated hepatocellular injury. Conclusion and Implications DF 2156A is a non-competitive allosteric inhibitor of both IL-8 receptors CXCR1 and CXCR2. It prevented experimental angiogenesis and hepatic I/R injury in vivo and, therefore, has therapeutic potential for acute and chronic inflammatory diseases.

AB - Background and Purpose DF 2156A is a new dual inhibitor of IL-8 receptors CXCR1 and CXCR2 with an optimal pharmacokinetic profile. We characterized its binding mode, molecular mechanism of action and selectivity, and evaluated its therapeutic potential. Experimental Approach The binding mode, molecular mechanism of action and selectivity were investigated using chemotaxis of L1.2 transfectants and human leucocytes, in addition to radioligand and [ 35S]-GTPγS binding approaches. The therapeutic potential of DF 2156A was evaluated in acute (liver ischaemia and reperfusion) and chronic (sponge-induced angiogenesis) experimental models of inflammation. Key Results A network of polar interactions stabilized by a direct ionic bond between DF 2156A and Lys99 on CXCR1 and the non-conserved residue Asp 293 on CXCR2 are the key determinants of DF 2156A binding. DF 2156A acted as a non-competitive allosteric inhibitor blocking the signal transduction leading to chemotaxis without altering the binding affinity of natural ligands. DF 2156A effectively and selectively inhibited CXCR1/CXCR2-mediated chemotaxis of L1.2 transfectants and leucocytes. In a murine model of sponge-induced angiogenesis, DF 2156A reduced leucocyte influx, TNF-α production and neovessel formation. In vitro, DF 2156A prevented proliferation, migration and capillary-like organization of HUVECs in response to human IL-8. In a rat model of liver ischaemia and reperfusion (I/R) injury, DF 2156A decreased PMN and monocyte-macrophage infiltration and associated hepatocellular injury. Conclusion and Implications DF 2156A is a non-competitive allosteric inhibitor of both IL-8 receptors CXCR1 and CXCR2. It prevented experimental angiogenesis and hepatic I/R injury in vivo and, therefore, has therapeutic potential for acute and chronic inflammatory diseases.

KW - binding mode

KW - chemokine receptors

KW - CXCR1/CXCR2

KW - experimental angiogenesis

KW - ischaemia reperfusion injury

KW - leucocyte recruitment

KW - non-competitive allosteric inhibitor

UR - http://www.scopus.com/inward/record.url?scp=83755220076&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=83755220076&partnerID=8YFLogxK

U2 - 10.1111/j.1476-5381.2011.01566.x

DO - 10.1111/j.1476-5381.2011.01566.x

M3 - Article

C2 - 21718305

AN - SCOPUS:83755220076

VL - 165

SP - 436

EP - 454

JO - British Journal of Pharmacology

JF - British Journal of Pharmacology

SN - 0007-1188

IS - 2

ER -